Other languages Innoviva, Inc.

Equities

INVA

US45781M1018

Real-time Estimate Cboe BZX Other stock markets 09:53:18 2024-04-29 am EDT			5-day change	1st Jan Change
15.22 ^USD	-0.23%		+1.94%	-5.11%

Apr. 24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	Apr. 24
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	Mar. 04
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	Feb. 06
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	Nov. 17
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01
Innoviva Names Stephen Basso as Finance Chief	23-08-28
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee	23-07-11
Insider Buy: Innoviva	23-05-31
Innoviva Unit Says FDA Approves Xacduro for Treatment of Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia	23-05-24
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Innoviva, Inc. Announces Retirement of George Bickerstaff, III, as Board Chairman	23-04-28
MÄRKTE USA/Wall Street dürfte Schwung des späten Vortageshandels halten	23-04-18
Innoviva Says FDA's Antimicrobial Drugs Advisory Committee to Convene in April to Review New Drug Application for Sulbactam-Durlobactam	23-03-14
Innoviva, Inc. Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic	23-03-13
Innoviva, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28
Zai Lab New Drug Application for Sulbactam-Durlobactam Accepted in China	23-02-22
Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors	23-01-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Innoviva, Inc.

Equities

INVA

US45781M1018

Other languages

Filters